Patient-focused drug development a new direction for collaboration

Medical Care

Volumn 53, Issue 1, 2015, Pages 9-17

  Perfetto, Eleanor M ^a   Burke, Laurie ^b   Oehrlein, Elisabeth M ^a   Epstein, Robert S ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b LORA Group   (United States)

^c EpsteinHealth   (United States)

Author keywords

Drug approval process; Drug development; Patient centered; patient engagement; Patient focused; Patient involvement

Indexed keywords

ALOSETRON; NATALIZUMAB; PROTON PUMP INHIBITOR;

ADVISORY COMMITTEE; ARTICLE; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG LEGISLATION; FOOD AND DRUG ADMINISTRATION; HUMAN; PATIENT ADVOCACY; PATIENT PARTICIPATION; COOPERATION; INSURANCE; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PEER REVIEW; PROCEDURES; RISK ASSESSMENT; UNITED STATES;

COOPERATIVE BEHAVIOR; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; INSURANCE CARRIERS; PATIENT PARTICIPATION; PATIENT-CENTERED CARE; PEER REVIEW, RESEARCH; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84919341393     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000273     Document Type: Article

References (41)

1. Patient Protection and Affordable Care Act, Pub L No. 111-148, 124 Stat 119 (2010).
2. Food and Drug Administration. Prescription Drug User Fee Act V patient-focused drug development; public meeting and request for comment. Fed Regist. 2012;77:58848-58849.
3. Mullin T. Patient-Focused Drug Development Public Meeting. Power Point Presentation, Silver Spring, MD; June 20, 2012.
4. About the FDA Patient Network About the Patient Representative Program. Available at: http://www.fda.gov/forpatients/about/ucm412709. htm. Accessed September 29, 2014.
5. Patel N. A patient-centered approach. 2012. Available at: http://www.fda. gov/downloads/forhealthprofessionals/articlesofinterest/ucm302525.pdf. Accessed September 29, 2014.
6. Sentinel Initiative-Transforming How We Monitor Product Safety FDAs Sentinel Initiative-Deliverables from Completed Contracts. Available at: http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149343. htm. Accessed October 14, 2014.
7. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed October 14, 2014.
8. Burke L. Talk presented at: ISPOR 18th Annual International Meeting Plenary Session. 2013; New Orleans, Louisiana. 2013. Available at: http://www.ispor.org/meetings/neworleans0513/releasedpresentations/Second-Plenary-Laurie-Burke.pdf. Accessed September 24, 2014.
9. Bhosle MJ, Kulkarni A, Feldman SR, et al. Quality of life in patients with psoriasis. Health Qual Life Outcomes [serial online]. 2006;4:35. England.
10. Ginsburg IH, Link BG. Psychosocial consequences of rejection and stigma feelings in psoriasis patients. Int J Dermatol [serial online]. 1993;32:587-591. United States.
11. Food and Drug Administration. Food and Drug Administration Safety and Innovation Act, Pub L No. 122-144, 126 Stat 993.2012.
12. Food and Drug Administration. PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2013-2017, 2012. Available at: http://www.fda. gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm270412.pdf. Accessed October 18, 2013.
13. Mullin T. FDA Working with Patients to Explore Benefit/Risk: Opportunities &Challenges: Patient-Focused Drug Development. Power Point Presentation, May 18, 2012. Available at: http://www.fda.gov/ForPatients/About/ucm412666.htm.
14. Mullin T. Patient Focused Drug Development. Power Point Presentation, 2012. Available at: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM310754.pdf. Accessed September 24, 2014.
15. Food and Drug Administration Safety and Innovation Act (FDASIA) Fact Sheet: Increased Patient Participation in Medical Product Regulation. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/Federal FoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDC Act/FDASIA/ucm311045.htm. Accessed September 24, 2014.
16. Patient-Focused Drug Development: Disease Area Meetings Planned for Fiscal Years 2013-2015.2013. Available at: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm347317.htm. Accessed December 5, 2013.
17. Prescription Drug User Fee Act Patient-Focused Drug Development; Request for Comments. 79 FR 60857;2014.
18. Patient-Focused Drug Development ConsultationMeeting December 11, 2012 Meeting Minutes. 2012. Available at: http://www.fda.gov/ForIndustry/User-Fees/PrescriptionDrugUserFee/ucm349457.htm. Accessed December 5, 2013.
19. Narcolepsy Public Meeting on Patient-Focused Drug Development. 2/8/2014, 2013. Available at: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm359018.htm. Accessed February 8, 2014.
20. The Voice of the Patient A series of reports from the U.S. Food and Drug Administrations (FDAs) Patient-Focused Drug Development Initiative-Chronic Fatigue Syndrome and Myalgic Encephalomyelitis. 2013. Available at: http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM368806.pdf. Accessed February 7, 2014.
21. Prescription Drug User Fee Act (PDUFA) The Voice of the Patient: A Series of Reports from FDAs Patient-Focused Drug Development Initiative. Available at: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm368342.htm. Accessed October 8, 2014.
22. Putting Patients First: Recommendations to speed responsible access to new therapies for Duchenne muscular dystrophy and other rare, serious and life-Threatening neurologic disorders. Available at: http://www.parentprojectmd. org/site/PageServer?pagename=Advocate-patients. Accessed December 5, 2013.
23. Saltonstall P. NORD Comments Submitted to FDA on 5-Year Draft Plan Regarding Benefit/Risk. 2013. Available at: http://www.rarediseases. org/advocacy/policy-statements. Accessed December 5, 2013.
24. FDA Patient-Centric Initiative: Leading Patient Advocates Identify Factors Most Important to Success. Available at: http://powerofpartnering.com/Portals/0/10376-13%20Patient%20Advocacy%20FDA-PROOF.pdf. Accessed March 9, 2014.
25. Guidance for Industry Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: Developing Drug Products for Treatment (Draft Guidance). 2013. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM388568.pdf. Accessed May 19, 2014.
26. Patient Perspectives on Disease Impact and Treatment Options: A Stratification Tool, 2013. Available at: http://www.nationalhealthcouncil. org/NHC-Files/Pdf-Files/NHC-Patient-Stratification-Tool-w-Instructions. pdf. Accessed January 25, 2014.
27. TOUCH Prescribing Program, 2009. Available at: https://www.touch program.com/TTP/.
28. Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision-Making: Draft PDUFA Implementation Plan-February 2013 Fiscal Years 2013-2017, 2013. Available at: http://www.fda.gov/down oads/forindustry/userfees/prescriptiondruguserfee/ucm329758.pdf. Accessed October 18, 2013.
29. Woodcock J. Letter Regarding Lotronex from Dr. Janet Woodcock, Director, Center for Drug Evaluation and Research. 2000. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformation forpatientsandproviders/ucm110883.htm. Accessed February 7, 2014.
30. Dear Irritable Bowel Syndrome (IBS) Patient (1/24/2002) Lotronex Information, 2002. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm110865.htm. Accessed February 5, 2014.
31. Terry S. Investing patients in the research and continuous improvement enterprise. In: Olsen L, Saunders RS, McGinnis JM, eds. Patients Charting the Course: Citizen Engagement in the Learning Health System: Workshop Summary. Washington, DC: National Academies Press; 2011:95-118.
32. Mullins C, Abdulhalim AM, Lavallee DC. Continuous patient engagement in comparative effectiveness research. JAMA [serial online]. 2012;307:1587-1588.
33. Lewis-Hall F. Talk presented at: ISPOR 18th Annual International Meeting Plenary Session 2013; New Orleans, Louisiana. Available at: http://www.ispor.org/meetings/neworleans0513/releasedpresentations/Second-Plenary-Freda-Lewis-Hall.pdf.
34. Expedited Programs for Serious Conditions-Drugs and Biologics (Draft Guidance), 2013. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301. pdf. Accessed December 5, 2013.
35. Perfetto E. Talk presented at: ISPOR 18th Annual International Meeting Plenary Session 2013; New Orleans, Louisiana. 2013. Available at: http://www.ispor.org/meetings/neworleans0513/releasedpresentations/IP5-Eleanor-Perfetto.pdf. Accessed November 22, 2013.
36. What We Mean by Engagement. Available at: http://www.pcori.org/content/what-we-mean-engagement#main. Accessed October 14, 2014.
37. Clinical Outcome Assessment (COA): Glossary of Terms, 2013. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm370262.htm. Accessed February 21, 2014.
38. Drug Development Tools Qualification Program Clinical Outcome Assessment Qualification Program. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualification Program/ucm284077.htm. Accessed October 13, 2014.
39. Food and Drug Administration. Food and Drug Administration Safety and Innovation Act (FDASIA) [Internet]. Silver Spring, MD. FDA. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDC Act/FDASIA/. Accessed October 18, 2013.
40. Food and Drug Administration. Prescription Drug User Fee Act V Patient-Focused Drug Development; Public Meeting and Request for Comment. Fed Regist. 2012;185:58848-58849. Available at: https://federalregister.gov/a/2012-23454.
41. Food and Drug Administration. Prescription Drug User Fee Act Patient-Focused Drug Development; Announcement of Disease Areas for Meetings Conducted in Fiscal Years 2013-2015. Fed Regist. 2013;70:21613-21614. Available at: https://federalregister.gov/a/2013-08441.